Table 1. Baseline clinical characteristics of 69 patients treated with FTY.
| Characteristic | All (n=69) | Gr-4 lymphopenia (n=7) | Non-Gr-4 lymphopenia (n=62) | p | |
|---|---|---|---|---|---|
| Age, years | 36.1±9.8 | 31.7±10.4 | 36.6±9.7 | 0.287 | |
| Onset age, years | 26.1±8 | 20.7±5.6 | 26.7±7.9 | 0.066 | |
| Sex, female | 44 (63.8) | 3 (42.9) | 41 (66.1) | 0.245 | |
| Age at initiation of FTY, years | 33.1±9.2 | 29.3±9.4 | 33.6±9.2 | 0.253 | |
| Body mass index, kg/m2 | 23.7±4.6 | 23.2±2.9 | 23.8±4.7 | 0.905 | |
| Body mass index <18.5 kg/m2 | 5 (7.2) | 0 (0) | 5 (8.1) | >0.999 | |
| Varicella zoster vaccination or VZV IgG-positive | 59 (85.5) | 6 (85.7) | 53 (85.5) | 1.000 | |
| Pretreatment ALC, /μL | 1,826±787.1 | 1,709.4±454.2 | 1,839.8±819.2 | 0.639 | |
| Pretreatment EDSS score | 2 [0–6] | 1 [0–4] | 2 [0–6] | 0.07 | |
| Pretreatment ARR | 1.2±1.3 | 1.1±1.1 | 1.2±1.4 | 0.564 | |
| DMT before FTY, numbers | 1.7±0.9 | 1.6±0.5 | 1.7±0.9 | >0.999 | |
| Recent DMT before FTY | |||||
| Interferon-β-Ia or -Ib | 25 (36.2) | 1 (14.3) | 24 (38.7) | 0.199 | |
| Glatiramer acetate | 5 (7.2) | 1 (14.3) | 4 (6.5) | 0.424 | |
| Dimethyl fumarate | 19 (27.5) | 2 (28.6) | 17 (27.4) | >0.999 | |
| Teriflunomide | 15 (21.7) | 3 (42.9) | 12 (19.4) | 0.169 | |
| Natalizumab | 2 (2.9) | 0 (0) | 2 (3.2) | >0.999 | |
| Alemtuzumab | 2 (2.9) | 0 (0) | 2 (3.2) | >0.999 | |
Data are mean±SD, n (%), or median [range] values.
ALC, absolute lymphocyte count; ARR, annualized relapse rate; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; FTY, fingolimod; Gr, grade; IgG, immunoglobulin G; SD, standard deviation; VZV, varicella zoster virus.